Charles River Completes the Acquisition of Cognate BioServices
New Manufacturing Capabilities Will Help Bring Your Products Across the Finish Line
Patients are waiting, and you need to get your novel cell and gene therapies to market. Working with a single partner throughout your program can achieve significant savings in time and resources.
Adding premier development and manufacturing capabilities to our comprehensive portfolio of support for your cell and gene therapy programs, our acquisition of Cognate BioServices and its Cobra Biologics facilities create a unique end-to-end solution for your development and delivery of novel cell and gene therapies.
Accelerated, Single-Source Development for Cell and Gene Therapies
Cognate and Cobra’s wide range of starting materials, comprehensive manufacturing solution for cell therapies, and production of plasmid DNA for gene therapies augment our existing line of human cellular products (via HemaCare and Cellero) and biologics testing solutions, completing the development lifecycle. Further expanding the breadth of scientific and regulatory expertise you’ll only find at Charles River, Cognate and Cobra’s scientific teams can offer experienced insight into optimizing the manufacturing stages of your cell and gene therapy development.
Now you can take your cell and gene therapies from early research and discovery all the way through commercialization in a single, streamlined program that saves time on the road to patients.